The success of mRNA-based therapeutics and vaccines is attributed to their rapid development, adaptability, and scalable production. Modified ribonucleotides like N 1-methylpseudouridine enhance ...

Lipid nanoparticles (LNPs) are the most clinically advanced nonviral RNA-delivery vehicles, though challenges remain in fully understanding how LNPs interact with biological systems. In vivo, proteins ...

Imagine a breakthrough in cancer treatment where only malignant cells are targeted, sparing healthy host cells; or patients with abnormal protein synthesis are treated to produce a healthy protein.

Nucleic acid-based therapeutics, including antisense oligonucleotides (ASO), small interfering RNA (siRNA), messenger RNA (mRNA), immunomodulatory DNA/RNA, and gene-editing guide RNA (gRNA), hold ...

The messenger ribonucleic acid (mRNA) vaccine technology that saved humanity from the novel coronavirus infection (COVID-19) is expanding its scope to the treatment of cancer, genetic disorders, and ...

Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Treated With Cyclin-Dependent Kinase ...

Imagine a cancer treatment that precisely targets malignant cells, leaving healthy ones untouched. Consider, also, a cancer treatment that corrects abnormal protein synthesis to produce healthy ...

Imagine a breakthrough in cancer treatment where only malignant cells are targeted, sparing healthy host cells; or patients with abnormal protein synthesis are treated to produce a healthy protein.

The mRNA therapeutics industry faces a critical manufacturing challenge that threatens both product safety and commercial viability. Double-stranded RNA (dsRNA) formation during in vitro transcription ...

What is an RNA vaccine? RNA vaccines, or messenger RNA (mRNA) vaccines, are a relatively new type of vaccine that delivers mRNA molecules to human cells, instructing them to produce specific antigens.

SAN FRANCISCO--(BUSINESS WIRE)--ParcelBio, a biotechnology company developing a new class of potent and durable mRNA medicines, today announced it has raised $13 million in seed financing led by ...

ParcelBio's co-founders Chris Carlson, PhD (left), and David Weinberg, PhD (right) [ParcelBio] Biotechnology company ParcelBio said this week that it has raised $13 million in a seed financing round ...